Edition:
United States

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

0.73USD
22 Feb 2019
Change (% chg)

$-0.55 (-42.99%)
Prev Close
$1.28
Open
$0.75
Day's High
$0.75
Day's Low
$0.71
Volume
378,899
Avg. Vol
33,054
52-wk High
$8.30
52-wk Low
$0.71

Chart for

About

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is... (more)

Overall

Beta: 2.05
Market Cap(Mil.): $14.25
Shares Outstanding(Mil.): 14.69
Dividend: --
Yield (%): --

Financials

  TRIL.OQ Industry Sector
P/E (TTM): -- 85.34 35.95
EPS (TTM): -4.07 -- --
ROI: -75.86 10.06 12.64
ROE: -643.63 10.28 13.82

Earnings vs. Estimates